Aclaris Therapeutics (NASDAQ:ACRS) Upgraded to Hold at StockNews.com

StockNews.com upgraded shares of Aclaris Therapeutics (NASDAQ:ACRS - Free Report) from a sell rating to a hold rating in a research note published on Friday.

Separately, HC Wainwright restated a "neutral" rating on shares of Aclaris Therapeutics in a research note on Tuesday, September 17th.

Aclaris Therapeutics Stock Down 6.0 %

Shares of ACRS stock traded down $0.13 during mid-day trading on Friday, reaching $2.05. 736,031 shares of the company's stock traded hands, compared to its average volume of 1,001,223. The company's 50-day moving average price is $1.47 and its 200-day moving average price is $1.30. The company has a market cap of $146.43 million, a P/E ratio of -3.94 and a beta of 0.10. Aclaris Therapeutics has a 12 month low of $0.77 and a 12 month high of $2.72.

Aclaris Therapeutics (NASDAQ:ACRS - Get Free Report) last posted its earnings results on Wednesday, November 6th. The biotechnology company reported ($0.11) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.08) by ($0.03). The company had revenue of $4.35 million for the quarter, compared to the consensus estimate of $8.31 million. Aclaris Therapeutics had a negative net margin of 136.65% and a negative return on equity of 40.26%. Equities analysts predict that Aclaris Therapeutics will post -0.65 earnings per share for the current year.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of ACRS. Mirae Asset Global Investments Co. Ltd. acquired a new stake in shares of Aclaris Therapeutics during the first quarter worth $39,000. BNP Paribas Financial Markets grew its stake in Aclaris Therapeutics by 10.9% during the 1st quarter. BNP Paribas Financial Markets now owns 241,101 shares of the biotechnology company's stock valued at $299,000 after purchasing an additional 23,747 shares during the last quarter. SG Americas Securities LLC increased its holdings in shares of Aclaris Therapeutics by 69.5% in the first quarter. SG Americas Securities LLC now owns 32,843 shares of the biotechnology company's stock valued at $41,000 after purchasing an additional 13,461 shares during the period. Russell Investments Group Ltd. raised its stake in shares of Aclaris Therapeutics by 5,265.1% in the first quarter. Russell Investments Group Ltd. now owns 62,772 shares of the biotechnology company's stock worth $78,000 after purchasing an additional 61,602 shares during the last quarter. Finally, Vanguard Group Inc. lifted its holdings in shares of Aclaris Therapeutics by 4.4% during the first quarter. Vanguard Group Inc. now owns 4,929,775 shares of the biotechnology company's stock worth $6,113,000 after purchasing an additional 207,418 shares during the period. Institutional investors own 98.34% of the company's stock.

Aclaris Therapeutics Company Profile

Aclaris Therapeutics, Inc a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases.